Blockade of sensory abnormalities and kinin B1 receptor expression by N-Acetyl-l-Cysteine and ramipril in a rat model of insulin resistance

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 66-72

  Ismael, Mahmoud Ali ^a   Talbot, Sébastien ^a   Carbonneau, Cynthia L ^b   Beauséjour, Christian M ^b   Couture, Réjean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

ACE inhibitor; Allodynia; Diabetes; Hypertension; Insulin resistance; N Acetyl l Cysteine; Oxidative stress; Pain neuropathy

Indexed keywords

ACETYLCYSTEINE; ACETYLLYSYLBRADYKININ[7 [3 (2 NAPHTHYL)ALANINE] 8 ISOLEUCINE 9 DEARGININE]; ANTIOXIDANT; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRINKING WATER; GLUCOSE; ICATIBANT; INSULIN; MESSENGER RNA; RAMIPRIL;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; COLD EXPOSURE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY CORTEX; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSORY NEUROPATHY; SPINAL CORD; SYSTOLIC BLOOD PRESSURE; TACTILE STIMULATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CYSTINE; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRINKING; EATING; GLUCOSE; HYPERALGESIA; HYPERTENSION; INSULIN; INSULIN RESISTANCE; KIDNEY CORTEX; MALE; PAIN MEASUREMENT; RAMIPRIL; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B1; RNA, MESSENGER; SENSATION; SPINAL CORD; TIME FACTORS;

EID: 47549096405     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.006     Document Type: Article

References (41)

1. 2 receptors. Br. J. Pharmacol. (2008) 1-8 Mar 3, [Electronic publication ahead of print]
2. Aoki S., Su Q., Li H., Nishikawa K., Ayukawa K., Hara Y., Namikawa K., Kiryu, Seo S., Kiyama H., and Wada K. Identification of an axotomy-induced glycosylated protein, AIGP1, possibly involved in cell death triggered by endoplasmic reticulum-Golgi stress. J. Neurosci. 22 (2002) 10751-10760
3. Bertrand M.E. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr. Med. Res. Opin. 20 (2004) 1559-1569
4. Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., and Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28 (2005) 956-962
5. Brown M.J., and Asbury A.K. Diabetic neuropathy. Ann. Neurol 15 (1984) 2-12
6. Cai H., Griendling K.K., and Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci 24 (2003) 471-478
7. Cameron N.E., Cotter M.A., Archibald V., Dines K.C., and Maxfield E.K. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37 (1994) 449-459
8. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53 (1994) 55-63
9. Choi Y., Yoon Y.W., Na H.S., Kim S.H., and Chung J.M. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 59 (1994) 369-376
10. Clark Jr. C.M., and Lee D.A. Prevention and treatment of the complications of diabetes mellitus. N. Engl. J. Med 332 (1995) 1210-1217
11. Cooper A.J., and Kristal B.S. Multiple roles of glutathione in the central nervous system. Biol. Chem 378 (1997) 793-802
12. Couture R., and Girolami J.P. Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur. J. Pharmacol 500 (2004) 467-485
13. Daousi C., MacFarlane I.A., Woodward A., Nurmikko T.J., Bundred P.E., and Benbow S.J. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet. Med. 21 (2004) 976-982
14. Dias J.P., Ismael M.A., Pilon M., de Champlain J., Ferrari B., Carayon P., and Couture R. The kinin B(1) receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br. J. Pharmacol. 152 (2007) 280-287
15. Dimitropoulou C., Chatterjee A., McCloud L., Yetik-Anacak G., and Catravas J.D. Angiotensin, bradykinin and the endothelium. Handb. Exp. Pharmacol. 176 Pt 1 (2006) 255-294
16. El Midaoui A., Ongali B., Petcu M., Rodi D., de Champlain J., Neugebauer W., and Couture R. Increases of spinal kinin receptor binding sites in two rat models of insulin resistance. Peptides 26 (2005) 1323-1330
17. El Midaoui A., Ismael M.A., Lu H., Fantus G.I., de Champlain J., and Couture R. Comparative effects of N-acetyl-l-cysteine and ramipril on arterial hypertension, insulin resistance and oxidative stress in chronically glucose-fed rats. Can. J. Diabetes 1 (2006) Suppl., Sept 2006 Issue, Abstract 31
18. Forbes J.M., Cooper M.E., Thallas V., Burns W.C., Thomas M.C., Brammar G.C., Lee F., Grant S.L., Burrell L.A., Jerums G., and Osicka T.M. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51 (2002) 3274-3282
19. Girouard H., Chulak C., Wu L., Lejossec M., and de Champlain J. N-acetylcysteine improves nitric oxide and alpha-adrenergic pathways in mesenteric beds of spontaneously hypertensive rats. Am. J. Hypertens. 16 (2003) 577-584
20. Gorus F.K., Weets I., Couck P., and Pipeleers D.G. Epidemiology of type 1 and type 2 diabetes. The added value of diabetes registries for conducting clinical studies: the Belgian paradigm. Acta Clin.Belg. 59 (2004) 1-13
21. Henriksen E.J., Jacob S., Augustin H.J., and Dietze G.J. Glucose transport activity in insulin-resistant rat muscle. Effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes 45 Suppl 1 (1996) S125-S128
22. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
23. Landmesser U., and Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J. Hypertens. 24 (2006) S39-43 Suppl.
24. Leeb-Lundberg L.M., Marceau F., Müller-Esterl W., Pettibone D.J., and Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57 (2005) 27-77
25. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
26. Love A., Cotter M.A., and Cameron N.E. Effects of the sulphydryl donor N-acetyl-l-cysteine on nerve conduction, perfusion, maturation and regeneration following freeze damage in diabetic rats. Eur.J.Clin.Invest 26 (1996) 698-706
27. 1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance. Neuropeptides 41 (2007) 375-387
28. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
29. McFarlane S.I., Kumar A., and Sowers J.R. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol. 91 (2003) 30H-37H
30. Moncada S. Nitric oxide and cell respiration: physiology and pathology. Verh. K. Acad. Geneeskd. Belg 62 (2000) 171-179
31. Nagamatsu M., Nickander K.K., Schmelzer J.D., Raya A., Wittrock D.A., Tritschler H., and Low P.A. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18 (1995) 1160-1167
32. 125I-brain paste standards for use in quantitative receptor autoradiography. J. Neurosci. Methods 30 (1989) 247-253
33. Ongali B., Buck H.S., Cloutier F., Legault F., Regoli D., Lambert C., Thibault G., and Couture R. Chronic effects of angiotensin-converting enzyme inhibition on kinin receptor binding sites in the rat spinal cord. Am. J. Physiol. (Heart Circ. Physiol) 284 (2003) H1949-H1958
34. Sagara M., Satoh J., Wada R., Yagihashi S., Takahashi K., Fukuzawa M., Muto G., Muto Y., and Toyota T. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 39 (1996) 263-269
35. Sharma S.S., Kumar A., and Kaundal R.K. Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci. 82 (2008) 570-576
36. Song D., Hutchings S., and Pang C.C. Chronic N-acetylcysteine prevents fructose-induced insulin resistance and hypertension in rats. Eur. J. Pharmacol 508 (2005) 205-210
37. Vincent A.M., Russell J.W., Low P., and Feldman E.L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev 25 (2004) 612-628
38. Wada R., Tifft C.J., and Proia R.L. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. U. S. A. 97 20 (2000) 10954-10959
39. 1 receptor antagonist. Eur. J. Pharmacol 205 (1991) 217-218
40. Woods S.E., Smith J.M., Sohail S., Sarah A., and Engle A. The influence of type 2 diabetes mellitus in patients undergoing coronary artery bypass graft surgery: an 8-year prospective cohort study. Chest 126 (2004) 1789-1795
41. Yavuz D., Koc M., Toprak A., Akpinar I., Velioglu A., Deyneli O., Haklar G., and Akalin S. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J. Renin-Angiotensin-Aldosterone Syst. 4 (2003) 197-203